SANGUINATE™

BIOLOGICAL4 trials

Sponsors

Prolong Pharmaceuticals

Conditions

Acute AnemiaCerebral IschemiaDrug SafetySickle Cell Disease

Phase 1

An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers.

TerminatedNCT01847222

Prolong PharmaceuticalsDrug Safety

Start: 2013-05-31End: 2014-08-31Updated: 2015-01-06

Study of SANGUINATE™ Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients

CompletedNCT01848925

Prolong PharmaceuticalsSickle Cell Disease

Start: 2013-05-31End: 2014-08-31Updated: 2014-12-03

A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.

CompletedNCT02754999

Prolong PharmaceuticalsAcute Anemia

Start: 2016-03-31End: 2017-05-17Updated: 2017-06-27

Phase 2

Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) Following Subarachnoid Hemorrhage (SAH)

CompletedNCT02323685

Prolong PharmaceuticalsCerebral Ischemia

Start: 2014-12-31End: 2016-10-31Updated: 2016-10-27

Related Papers

Expanded Access Use of Sanguinate Saves Lives: Over 100 Cases Including 14 Previously Published Cases

Anesthesia Research2025-06-29